VCA
CLBT icon

Verdence Capital Advisors’s Cellebrite CLBT Stock Holding History

Verdence Capital Advisors’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$339K Sell
23,197
-1,188
-5% -$15.7K 0.02% 516
2026
Q1 		$336K Buy
24,385
+14,141
+138% +$213K 0.02% 506
2025
Q4 		$185K Buy
+10,244
New +$184K 0.01% 625

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Verdence Capital Advisors's CLBT Position: Q2 2026 in Review

Verdence Capital Advisors reduced its Cellebrite (CLBT) stake by 4.9% in Q2 2026, selling an estimated $15.7K and leaving 23,197 shares worth $339K. The position accounts for 0.02% of the portfolio, ranked #516.

Verdence Capital Advisors first reported a position in CLBT in Q4 2025 and has held it in 3 quarters since. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • Verdence Capital Advisors held 23,197 shares of Cellebrite worth $339K as of Q2 2026.
  • Verdence Capital Advisors sold 1,188 Cellebrite shares in Q2 2026, an estimated $15.7K.
  • Cellebrite made up 0.02% of Verdence Capital Advisors's portfolio in Q2 2026, its #516 holding.
  • Verdence Capital Advisors first reported a position in Cellebrite in Q4 2025 and has held it in 3 quarters since.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Verdence Capital Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.